Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PF-04691502

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

mTOR inhibitor, PI3K inhibitor

Related drugs:

‹

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

enzastaurin (3)

BAY 1082439 (1)

›

PTEN deletion	Ovarian Cancer	PTEN deletion	Ovarian Cancer	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D
KRAS G12D	Ovarian Cancer	KRAS G12D	Ovarian Cancer	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D
PTEN deletion	Ovarian Cancer	PTEN deletion	Ovarian Cancer	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D
KRAS G12D	Ovarian Cancer	KRAS G12D	Ovarian Cancer	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + PF-04691502 Sensitive: D – Preclinical quizartinib + PF-04691502 Sensitive : D	quizartinib + PF-04691502 Sensitive: D – Preclinical quizartinib + PF-04691502 Sensitive : D
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D